Cargando…

eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study

BACKGROUND: Shrunken Pore Syndrome (SPS), defined as a reduced ratio between two estimated filtration rates (based on cystatin C and creatinine) is an increasingly recognized risk factor for long-term mortality. Although some patients with other conditions might be erroneously identified as SPS. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Avotins, Lauris, Kroica, Juta, Petersons, Aivars, Zentina, Dace, Kravale, Zaiga, Saulite, Anna, Racenis, Karlis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500727/
https://www.ncbi.nlm.nih.gov/pubmed/37704948
http://dx.doi.org/10.1186/s12882-023-03315-x
_version_ 1785105971358466048
author Avotins, Lauris
Kroica, Juta
Petersons, Aivars
Zentina, Dace
Kravale, Zaiga
Saulite, Anna
Racenis, Karlis
author_facet Avotins, Lauris
Kroica, Juta
Petersons, Aivars
Zentina, Dace
Kravale, Zaiga
Saulite, Anna
Racenis, Karlis
author_sort Avotins, Lauris
collection PubMed
description BACKGROUND: Shrunken Pore Syndrome (SPS), defined as a reduced ratio between two estimated filtration rates (based on cystatin C and creatinine) is an increasingly recognized risk factor for long-term mortality. Although some patients with other conditions might be erroneously identified as SPS. Our aim was to bring the focus on possible pathophysiologic mechanisms influencing the ratio in the setting of SARS-CoV-2 pneumonia and acute kidney injury. METHODS: A single-centered prospective cohort study was conducted to investigate biomarkers in symptomatic COVID-19 pneumonia patients admitted to a hospital in Latvia. Nineteen biomarkers were measured in blood and three in urine samples. Associations were sought between these biomarkers, chronic diseases and the estimated GFR(cystatinC)/eGFR(creatinine) ratio < 0.6, mortality rates, and acute kidney injury development. Data analysis was performed using SPSS Statistics, with significance set at p < 0.05. RESULTS: We included 59 patients (average age 65.5 years, 45.8% female) admitted with COVID-19. Acute kidney injury occurred in 27.1%, and 25.4% died. Ratio < 0.6 was seen in 38.6%, associated with female sex, diabetes, hypothyroidism, and higher age. Ratio < 0.6 group had mortality notably higher − 40.9% vs. 16.2% and more cases of acute kidney injury (40.9% vs. 18.9%). Cystatin C showed strong associations with the ratio < 0.6 compared to creatinine. Urea levels and urea/creatinine ratio were higher in the ratio < 0.6 group. After excluding acute kidney injury patients, ratio < 0.6 remained associated with higher cystatin C and urea levels. Other biomarkers linked to a kidney injury as NGAL, and proteinuria did not differ. CONCLUSION: We prove that reduced ratio is common in hospitalized patients with SARS-CoV-2 pneumonia and is associated with increased mortality during hospitalization. Factors that influence this ratio are complex and, in addition to the possible shrinkage of pores, other conditions such as thickening of glomerular basal membrane, comorbidities, prerenal kidney failure and others may play an important role and should be addressed when diagnosing SPS. We highlight the need for additional diagnostic criteria for SPS and larger studies to better understand its implications in acute COVID-19 settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03315-x.
format Online
Article
Text
id pubmed-10500727
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105007272023-09-15 eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study Avotins, Lauris Kroica, Juta Petersons, Aivars Zentina, Dace Kravale, Zaiga Saulite, Anna Racenis, Karlis BMC Nephrol Research BACKGROUND: Shrunken Pore Syndrome (SPS), defined as a reduced ratio between two estimated filtration rates (based on cystatin C and creatinine) is an increasingly recognized risk factor for long-term mortality. Although some patients with other conditions might be erroneously identified as SPS. Our aim was to bring the focus on possible pathophysiologic mechanisms influencing the ratio in the setting of SARS-CoV-2 pneumonia and acute kidney injury. METHODS: A single-centered prospective cohort study was conducted to investigate biomarkers in symptomatic COVID-19 pneumonia patients admitted to a hospital in Latvia. Nineteen biomarkers were measured in blood and three in urine samples. Associations were sought between these biomarkers, chronic diseases and the estimated GFR(cystatinC)/eGFR(creatinine) ratio < 0.6, mortality rates, and acute kidney injury development. Data analysis was performed using SPSS Statistics, with significance set at p < 0.05. RESULTS: We included 59 patients (average age 65.5 years, 45.8% female) admitted with COVID-19. Acute kidney injury occurred in 27.1%, and 25.4% died. Ratio < 0.6 was seen in 38.6%, associated with female sex, diabetes, hypothyroidism, and higher age. Ratio < 0.6 group had mortality notably higher − 40.9% vs. 16.2% and more cases of acute kidney injury (40.9% vs. 18.9%). Cystatin C showed strong associations with the ratio < 0.6 compared to creatinine. Urea levels and urea/creatinine ratio were higher in the ratio < 0.6 group. After excluding acute kidney injury patients, ratio < 0.6 remained associated with higher cystatin C and urea levels. Other biomarkers linked to a kidney injury as NGAL, and proteinuria did not differ. CONCLUSION: We prove that reduced ratio is common in hospitalized patients with SARS-CoV-2 pneumonia and is associated with increased mortality during hospitalization. Factors that influence this ratio are complex and, in addition to the possible shrinkage of pores, other conditions such as thickening of glomerular basal membrane, comorbidities, prerenal kidney failure and others may play an important role and should be addressed when diagnosing SPS. We highlight the need for additional diagnostic criteria for SPS and larger studies to better understand its implications in acute COVID-19 settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03315-x. BioMed Central 2023-09-13 /pmc/articles/PMC10500727/ /pubmed/37704948 http://dx.doi.org/10.1186/s12882-023-03315-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Avotins, Lauris
Kroica, Juta
Petersons, Aivars
Zentina, Dace
Kravale, Zaiga
Saulite, Anna
Racenis, Karlis
eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
title eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
title_full eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
title_fullStr eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
title_full_unstemmed eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
title_short eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
title_sort egfr(cystatinc)/egfr(creatinine) ratio < 0.6 in patients with sars-cov-2 pneumonia: a prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500727/
https://www.ncbi.nlm.nih.gov/pubmed/37704948
http://dx.doi.org/10.1186/s12882-023-03315-x
work_keys_str_mv AT avotinslauris egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy
AT kroicajuta egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy
AT petersonsaivars egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy
AT zentinadace egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy
AT kravalezaiga egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy
AT sauliteanna egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy
AT raceniskarlis egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy